Home > PE Ratio > HIKAL

HIKAL
PE (Price/Earnings) Ratio

The Current P/E Ratio of HIKAL is 59.62.

Share Price ₹355.5Jan 31,2025
Market Cap ₹4,382.7 Cr
Earnings-TTM₹73.5 CrTTM-Consolidated Results
Price/Earnings59.62xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for HIKAL
Please provide your vote to see the results
HIKAL is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of HIKAL

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of HIKAL is calculated as :

Current Market Cap [ ₹4,382.7 Cr] as on Jan 31,2025

(/) Earnings [ ₹73.5 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 59.62x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for HIKAL , the investors are currently willing to pay 59.62 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of HIKAL !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of HIKAL over the last five years.

Historical PE (Price/Earnings) ratio chart of HIKAL


PE Ratio Performance Analysis for HIKAL

- HIKAL 's latest p/e ratio is 59.62x.

- HIKAL 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 29.14x.

- HIKAL 's operated at median p/e ratio of 30.92x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, HIKAL 's p/e ratio peaked in Mar2024 at 46.91x.

- HIKAL 's p/e ratio hit its five-year low in Mar2020 of 10.22x.


How does HIKAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
HIKAL 73.5159.624,382.7
SUN PHARMACEUTICAL INDUSTRIES LTD11,486.0036.41418,228.0
CIPLA LTD5,000.4323.89119,474.0
DR REDDYS LABORATORIES LTD5,428.6018.72101,599.0
ZYDUS LIFESCIENCES LTD4,298.9022.7097,604.7
DIVIS LABORATORIES LTD1,836.0080.62148,023.0
MANKIND PHARMA LTD2,050.7349.03100,540.0
TORRENT PHARMACEUTICALS LTD1,862.0059.24110,306.0
LUPIN LTD2,651.9435.8294,984.6
AUROBINDO PHARMA LTD3,598.8318.9168,055.4
ABBOTT INDIA LTD1,284.6643.2555,558.7

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs HIKAL 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 18.72x
Max industry PE 80.62x
Median industry PE 36.41x
Average industry PE 40.75x



You may also like the below Video Courses